Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Medicine in Bronchial Asthma
share announcement

Personalized Medicine in Bronchial Asthma

A special issue of Journal of Personalized Medicine (ISSN 2075-4426).

Deadline for manuscript submissions: closed (10 July 2022) | Viewed by 11825

Special Issue Editor

Dr. Paraskevi Katsaounou

E-Mail Website
Guest Editor
1. Pulmonary Dept of First ICU Clinic, Evangelismos Hospital, 10676 Athens, Greece
2. School of Medicine, National and Kapodistrian University of Athens, 10561 Athens, Greece
Interests: infections; COVID-19; smoking cessation; asthma; ergospirometry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Asthma is a heterogeneous disease comprising several phenotypes or endotypes driven by different pathways. Therefore, we need to start applying personalized medicine at all levels of asthma severity to address asthmatic patients’ needs. 

The aim is to highlight phenotypes, endotypes, and personal traits that could lead to increased susceptibility to the disease or heightened incidences, and to then use this information as a basis for which tailor-made prevention and treatment strategies can be devised for individuals or groups of patients such that they can receive specific therapies, i.e., the optimal medications that work best for them at the right time without wasting resources on trial and error treatments.

Another aim is to address additional factors such as environmental, occupational, psychological, and personality factors which are capable of affecting asthma management but are often ignored.

Evidence seems to indicate that genetic factors as well as others in a patient’s profile, such as obesity, smoking, and psychiatric and psychological factors may contribute to lack of asthma control.

For this Special Issue, we welcome research papers, clinical trials, and reviews addressing factors that could contribute to the use of personalized approaches in addressing asthma.

Dr. Paraskevi Katsaounou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Asthma
  • Phenotype
  • Endotype
  • Personalized medicine
  • Biomarkers

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 942 KiB  
Article
Daily Physical Activity in Asthma and the Effect of Mepolizumab Therapy
by Marios Panagiotou, Nikolaos Koulouris, Antonia Koutsoukou and Nikoletta Rovina
J. Pers. Med. 2022, 12(10), 1692; https://doi.org/10.3390/jpm12101692 - 11 Oct 2022
Cited by 2 | Viewed by 1353
Abstract
For the various asthma-specific beneficial effects of physical activity, daily physical activity (DPA) and the potential of asthma therapies on DPA require better characterization. Hence, we aimed to determine (a) the DPA of asthma patients, and (b) the effect of add-on mepolizumab on [...] Read more.
For the various asthma-specific beneficial effects of physical activity, daily physical activity (DPA) and the potential of asthma therapies on DPA require better characterization. Hence, we aimed to determine (a) the DPA of asthma patients, and (b) the effect of add-on mepolizumab on the DPA of severe asthma patients. Methods: Adult outpatients with mild-to-moderate or severe asthma had accelerometer assessment of DPA. Severe asthma patients who were commenced on mepolizumab had their DPA reassessed after 12 months. Results: For the total cohort (n = 36), daily step count, time in moderate-to-vigorous physical activity (MVPA), MVPA volume and Movement Intensity (MI) were 7806 ± 3823 steps, 123 (interquartile range, 63) min, 657 ± 255 MET·min and 1.96 (0.45) m/s2, respectively. All patients met at least one recommendation for DPA but less than half met recommendations for vigorous DPA. Patients on mepolizumab therapy increased daily step count (646 steps; 9%), time in MVPA (20 min; 21%), MVPA volume (87 MET·min; 17%) and MI (0.11 m/s2; 6%) for the same amount of moving time; lung function, asthma control and health-related quality of life also improved. Conclusions: Analysis of the first national data on DPA in asthma and novel comparison against current applicable guidelines and identified beneficial thresholds showed borderline levels of DPA with room for improvement especially for severe asthma patients. In a non-sedentary cohort of severe asthma patients, mepolizumab conferred significant and meaningful improvements in DPA. Full article
(This article belongs to the Special Issue Personalized Medicine in Bronchial Asthma)
►▼ Show Figures

Figure 1

7 pages, 537 KiB  
Article
Depression Levels Influence the Rate of Asthma Exacerbations in Females
by Papaporfyriou Anastasia, Tseliou Eleni, Mizi Eleftheria, Ntontsi Xenia, Papathanasiou Eygenia, Souliotis Kyriakos, Dimakou Katerina, Bakakos Petros, Loukides Stelios and Hillas Georgios
J. Pers. Med. 2021, 11(6), 586; https://doi.org/10.3390/jpm11060586 - 21 Jun 2021
Cited by 9 | Viewed by 2408
Abstract
Background: Anxiety and depression are common psychological disturbances among asthmatic patients. The aim of the present study is the assessment of anxiety and depression in asthmatic patients and their correlation with symptoms control level and number of exacerbations per year. Methods: [...] Read more.
Background: Anxiety and depression are common psychological disturbances among asthmatic patients. The aim of the present study is the assessment of anxiety and depression in asthmatic patients and their correlation with symptoms control level and number of exacerbations per year. Methods: One hundred patients with asthma diagnosis, according to the Global Initiative for Asthma (GINA), aged > 18 years old, having a stable disease, were included. Emotional status was evaluated using the Hospital Anxiety Depression Scale (HADS). Patients were followed up for a year to assess the number and severity of exacerbations. Results: Most of our patients were female (58%), middle-aged (mean = 54 ± 13), and married (81%), with low frequency of smoking habits (smokers, ex-smokers and non-smokers were 26%, 30% and 37%, respectively) and low levels of both anxiety and depression [median (interquartile range (IQR)) = 4(2) and median (IQR) = 4(2), respectively]. At the low and moderate level of the depression subscale, female patients experienced asthma exacerbations more frequently compared to male patients (adjusted Incidence Rate Ratio (aIRR) = 4.30; 95% Confidence Interval (CI): 1.94–9.53 and aIRR = 1.82; 95% CI: 1.07–3.13, respectively). Conclusions. Clinicians should evaluate asthma patients for depression, as gender differentially influences outcomes among those with low and moderate levels of depression, with female asthmatics presenting more frequent exacerbations. Full article
(This article belongs to the Special Issue Personalized Medicine in Bronchial Asthma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 394 KiB  
Review
Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
by Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta and Konstantinos Porpodis
J. Pers. Med. 2022, 12(2), 165; https://doi.org/10.3390/jpm12020165 - 26 Jan 2022
Cited by 6 | Viewed by 3912
Abstract
Omalizumab is the first monoclonal antibody that was globally approved as a personalized treatment option for patients with moderate-to-severe allergic asthma. This review summarizes the knowledge of almost two decades of use of omalizumab to answer some important everyday clinical practice questions, concerning [...] Read more.
Omalizumab is the first monoclonal antibody that was globally approved as a personalized treatment option for patients with moderate-to-severe allergic asthma. This review summarizes the knowledge of almost two decades of use of omalizumab to answer some important everyday clinical practice questions, concerning its efficacy and safety and its association with other asthma-related and drug-related parameters. Evidence suggests that omalizumab improves asthma control and reduces the incidence and frequency of exacerbations in patients with severe allergic asthma. Omalizumab is also effective in those patients in reducing corticosteroid use and healthcare utilization, while it also seems to improve lung function. Several biomarkers have been recognized in predicting its efficacy in its target group of patients, while the optimal duration for evaluating its efficacy is between 16 and 32 weeks. Full article
(This article belongs to the Special Issue Personalized Medicine in Bronchial Asthma)
29 pages, 662 KiB  
Review
Electronic Cigarettes and Asthma: What Do We Know So Far?
by Serafeim-Chrysovalantis Kotoulas, Paraskevi Katsaounou, Renata Riha, Ioanna Grigoriou, Despoina Papakosta, Dionysios Spyratos, Konstantinos Porpodis, Kalliopi Domvri and Athanasia Pataka
J. Pers. Med. 2021, 11(8), 723; https://doi.org/10.3390/jpm11080723 - 27 Jul 2021
Cited by 11 | Viewed by 2900
Abstract
Electronic cigarettes (EC) are a novel product, marketed as an alternative to tobacco cigarette. Its effects on human health have not been investigated widely yet, especially in specific populations such as patients with asthma. With this review, we use the existing literature in [...] Read more.
Electronic cigarettes (EC) are a novel product, marketed as an alternative to tobacco cigarette. Its effects on human health have not been investigated widely yet, especially in specific populations such as patients with asthma. With this review, we use the existing literature in order to answer four crucial questions concerning: (1) ECs’ role in the pathogenesis of asthma; (2) ECs’ effects on lung function and airway inflammation in patients with asthma; (3) ECs’ effects on asthma clinical characteristics in asthmatics who use it regularly; and (4) ECs’ effectiveness as a smoking cessation tool in these patients. Evidence suggests that many EC compounds might contribute to the pathogenesis of asthma. Lung function seems to deteriorate by the use of EC in this population, while airway inflammation alters, with the aggravation of T-helper-type-2 (Th2) inflammation being the most prominent but not the exclusive effect. EC also seems to worsen asthma symptoms and the rate and severity of exacerbations in asthmatics who are current vapers, whilst evidence suggests that its effectiveness as a smoking cessation tool might be limited. Asthmatic patients should avoid using EC. Full article
(This article belongs to the Special Issue Personalized Medicine in Bronchial Asthma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop